Chapter 4

Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder

Damiaan Denys*
Froukje E. de Vries*
Danielle C. Cath
Martijn Figee
Nienke C. Vulink
Dick J. Veltman
Thalia F. van der Doef
Ronald Boellaard
Herman Westenberg
Anton J.L.M. van Balkom
Adriaan A. Lammertsma
Bart N.M. van Berckel
*Both authors contributed equally.

Published in: European Neuropsychopharmacology, 2013 Nov;23(11) pp 1423-31
Abstract

Tourette syndrome (TS) and obsessive-compulsive disorder (OCD) both are neuropsychiatric disorders associated with abnormalities in dopamine neurotransmission. Aims of this study were to quantify striatal $D_{2/3}$ receptor availability in TS and OCD, and to examine dopamine release and symptom severity changes in both disorders following amphetamine challenge.

Changes in $[11C]raclopride$ binding potential ($BP_{ND}$) were assessed using positron emission tomography before and after administration of d-amphetamine ($0.3$ mg.kg$^{-1}$) in twelve TS patients without comorbid OCD, twelve OCD patients without comorbid tics, and twelve healthy controls. Main outcome measures were baseline striatal $D_{2/3}$ receptor $BP_{ND}$ and change in $BP_{ND}$ following amphetamine as a measure of dopamine release.

Voxel-based analysis revealed significantly decreased baseline $[11C]raclopride$ $BP_{ND}$ in bilateral putamen of both patient groups versus healthy controls, differences being more pronounced in the TS than in the OCD group. Changes in $BP_{ND}$ following amphetamine were not significantly different between groups. Following amphetamine administration, tic severity increased in the TS group, which correlated with $BP_{ND}$ changes in right ventral striatum. Symptom severity in the OCD group did not change significantly following amphetamine challenge and was not associated with changes in $BP_{ND}$.

This study provides evidence for decreased striatal $D_{2/3}$ receptor availability in TS and OCD, presumably reflecting higher endogenous dopamine levels in both disorders. In addition, it provides the first direct evidence that ventral striatal dopamine release is related to the pathophysiology of tics.
Introduction

Tourette syndrome (TS) is a neuropsychiatric disorder characterized by the presence of vocal and motor tics (Robertson, 2000). Obsessive-compulsive disorder (OCD) is an anxiety disorder characterized by obsessions that cause anxiety, and compulsions aimed at reducing that anxiety (Leckman et al., 2010). There is considerable overlap between the two disorders in terms of clinical phenomenology, epidemiology, genetics, immunology, and treatment (Ferrao et al., 2009). Despite these commonalities, it is still not clear to which extent pathogenetic mechanisms in TS and OCD are similar, although it has been assumed that abnormalities in dopaminergic (DA) neurotransmission within fronto-striatal circuitry are of key importance in both disorders (Gerard and Peterson, 2003; Denys et al., 2004).

The dopamine hypothesis of TS and OCD is based predominantly on clinical evidence and molecular imaging studies. For example, dopamine receptor antagonists are effective as monotherapy in reducing tics in TS (Robertson, 2000) and as an adjunct to SSRIs in reducing symptoms in OCD (Bloch et al., 2006; Vulink et al., 2009). Moreover, dopamine agonists may provoke tics (Borcherding et al., 1990; Lowe et al., 1982) and induce obsessive-compulsive behavior (Borcherding et al., 1990; Lemus et al., 1991). Molecular imaging studies using radiotracers binding to DA receptors have yielded conflicting results in TS (Gerard and Peterson, 2003). Some studies have supported the hypothesis that DA receptors are involved (Gilbert et al., 2006; Singer et al., 2002; Wong et al., 2008; Albin et al., 2003), other studies failed to show differences (Turjanski et al., 1994; Albin et al., 2009; Meyer et al., 1999; George et al., 1994). There are only a few reports on DA receptor binding in OCD, but these consistently have shown evidence for decreased D$_2$ receptor availability (Denys et al., 2004; Olver et al., 2009; Perani et al., 2008).

The inconsistencies in previous molecular imaging studies in TS may be explained by a number of methodological factors, including limited power of positron emission tomography (PET) and single photon emission computerized tomography (SPECT) studies, heterogeneity within subject populations, especially with regard to symptom severity and comorbidity, and changes in DA receptor expression and/or function due to the clinical use of DA antagonists.

In the present study, we aimed to elucidate the role of DA neurotransmission in TS and OCD using the extensively validated PET tracer $^{[11]}$C]raclopride (Gunn et al., 1997; Innis et al., 2007). $^{[11]}$C]raclopride binds to D$_{2/3}$ receptors and may be used to evaluate in vivo receptor binding at rest, as well as capture more dynamic aspects of DA transmission. Indeed, the change in $^{[11]}$C]raclopride binding following amphetamine challenge, which increases endogenous DA levels, is considered an indirect measure of DA release (Laruelle, 2000). Furthermore, amphetamine administration has been associated with induction of tics and compulsive behaviors, especially when high doses are used (Borcherding et al., 1990; Castellanos et al., 1997). Consequently, measuring
changes in [11C]raclopride following amphetamine administration in TS and OCD patients may serve as a measure of symptom related DA release. Two previous studies using this paradigm reported increased [11C]raclopride displacement in the putamen in a sample of 5 TS patients (Singer et al., 2002) and, in an extended sample of 14 TS patients and 10 control subjects in the right ventral striatum (Wong et al., 2008). The majority of patients in the second study, however, had a comorbid diagnosis of OCD, which in itself may be associated with abnormalities in DA neurotransmission. The purpose of the present study was to directly compare baseline availability of striatal D2/3 receptors and amphetamine-induced DA release between TS patients without OCD, OCD patients without tics or TS, and healthy controls.

Methods

Subjects

Patients were recruited through referrals from the academic outpatient clinic for anxiety disorders of the Academic Medical Center (AMC) Amsterdam and GGZinGeest, Amsterdam. Healthy control subjects were recruited through advertisements.

All subjects were interviewed by trained psychiatrists and diagnoses were confirmed using the Structural Clinical Interview for DSM-IV axis I disorders (SCID-I) (First et al., 1999). Tic history and severity were assessed using the Yale Tic Symptom Check List and the Yale Global Tic Severity Scale (YGTSS) (Leckman et al., 1989) and obsessive-compulsive symptoms using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) (Goodman et al., 1989). Affective symptoms were assessed using the Hamilton Depression (HAM-D) and Anxiety (HAM-A) rating scales (Hamilton, 1960; Hamilton, 1959). Control subjects were included when there was no current or past psychiatric diagnosis. All subjects were free of psychotropic medication for at least six months. Nine TS subjects never had taken medication for their tics. One subject had used antipsychotic medication until one year before the study and two subjects had used an alpha2 agonist several years before inclusion. Seven OCD subjects had never used medication for their obsessive-compulsive symptoms, whereas five had used SSRIs until six months before the study. Two TS subjects and three OCD subjects had a history of comorbid depressive episodes, and one OCD subject had a comorbid panic disorder.

Subjects were excluded when they had a history of regular use of psychoactive drugs or a positive urine drug screen, a history of neurological disease, or more than one risk factor for cardiovascular disease. All subjects were in good physical health, based on medical history, physical examination, electrocardiogram, MRI of the brain and routine blood screening. Written informed consent from all subjects was obtained after a complete description of the study. Medical ethics committees of all participating centers approved the study protocol.
Radiochemistry and imaging procedures

[11C]raclopride was prepared as previously described (Bossong et al., 2009), in accordance with the EU guideline “Eudralix volume 4: good manufacturing practices”. The precursor O-desmethyl raclopride hydrobromide was provided by ABX, Radeberg, Germany.

PET scans were performed using an ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN, USA), which acquires 63 transaxial planes with an axial field of view of 15.5 cm, covering the entire brain. [11C]raclopride was delivered intravenously using a computerized infusion pump (MedRad, Beek, the Netherlands). A priming bolus of 28 mL, administered over 3.1 minutes, was followed by a constant infusion over 88 minutes at a rate of 0.15 mL×min⁻¹, resulting in a bolus to infusion ratio (Kbol) of 112 minutes (Carson et al., 1997). Mean injected dose was similar for controls, TS patients and OCD patients (708±125, 757±43 and 756±101 MBq, respectively; p>0.1). Forty minutes after start of [11C]raclopride administration, subjects were placed in the PET camera for a 40 minutes scanning period, consisting of 8 consecutive frames of 5 minutes. After emission scanning, a 10 minutes transmission scan was performed to correct for photon attenuation. Correction for emission contamination was performed using the dwell profile method (van der Werd et al., 2004). During scanning, subjects were immobilized with a custom made head holder. Subject motion was monitored continuously using laser beams, and corrected immediately when necessary. After the first PET scan, subjects could rest outside the camera for approximately two hours to allow for decay of carbon-11. Before the second scanning session, amphetamine (0.3 mgxkg⁻¹) was given intravenously over two minutes, directly followed by [11C]raclopride administration. The protocol for the second scanning session was identical to that of the first. Subjects were under constant cardiovascular monitoring during both scans. Measurements of symptom severity were performed before and after administration of amphetamine, while subjects were still outside the scanner. Both Y-BOCS and YGTSS were assessed immediately before injection, 20 minutes after injection of [11C]raclopride, and after completion of the scan (120 minutes after injection). Forty minutes after amphetamine administration, a venous sample was collected to assess amphetamine plasma levels using a procedure based on liquid chromatography-mass spectrometry (LC-MS). Amphetamine plasma levels were similar across groups (controls 48.3±10.2 μg/L, TS 51.4±12.6 μg/L, OCD 50.5±7.1 μg/L, p=0.77). All [11C]raclopride scans were reconstructed using FORE+2D FBP with a 0.5 Hanning filter, resulting in a transaxial spatial resolution of ~7 mm full width at half maximum (FWHM) in the centre of the field of view.

Structural T1 weighted MRI scans were acquired for all subjects on an Intera (Philips, Best, the Netherlands) 3T scanner (echo time, 4.6ms; repetition time, 30ms; flip angle, 30°; resolution, 0.89x0.89x1mm).
Data analysis

Non-displaceable binding potential ($\text{BP}_{\text{ND}}$) of $[^{11}\text{C}]$raclopride (Innis et al., 2007) was used as measure of $D_{2/3}$ receptor availability. Primary outcome parameters were baseline $\text{BP}_{\text{ND}}$ and the reduction in $\text{BP}_{\text{ND}}$ ($\Delta \text{BP}_{\text{ND}}$) induced by amphetamine. $\text{BP}_{\text{ND}}$ was defined as the distribution volume ratio (DVR) minus one (Lammertsma et al., 1996). As scans were performed during steady state, DVR corresponds with the ratio between activity concentrations in target ($C_T$) and reference ($C_{\text{CBL}}$) tissues. Cerebellum, which is devoid of $D_{2/3}$ receptors, was used as reference tissue. Each PET frame was individually co-registered to the structural T1 scan to correct for motion between frames. For both baseline and amphetamine scans, parametric $\text{BP}_{\text{ND}}$ maps were generated from the summed PET images using $\text{BP}_{\text{ND}}= (C_T - C_{\text{CBL}})/C_{\text{CBL}}$. To assess whether steady state conditions were achieved, $[^{11}\text{C}]$raclopride concentrations were calculated for all eight frames of each scan. Changes in concentration between frames were minimal (slopes varied between -0.01 and -0.02) and these changes were similar across groups and between conditions.

A voxel-based analysis of these parametric images was performed using SPM2 (Wellcome Trust Center for Neuroimaging, London, UK). The structural MRI of each subject was normalized to the SPM T1-MRI template and subsequently this transformation was applied to the co-registered parametric $\text{BP}_{\text{ND}}$ images. Normalized PET scans were smoothed using a 5 mm Gaussian filter resulting in an overall resolution of 8.5 mm FWHM. To limit the search volume, a functional mask of the striatum was created from the main effect of displacement in all subjects (baseline $\text{BP}_{\text{ND}}$ > post-amphetamine $\text{BP}_{\text{ND}}$). This mask was used in all of the following analyses. Voxel-wise one-way ANOVA was used to assess the location of peak differences between groups at baseline, which are reported at a threshold of $p<0.05$ with Family Wise Error (FWE) correction for the search volume. Results at $p<0.005$ uncorrected are reported as trends. Displacement was assessed using a voxel-wise one-way ANOVA with $\Delta \text{BP}_{\text{ND}}$ images, created by subtracting amphetamine images from baseline images for each subject. Mean baseline $\text{BP}_{\text{ND}}$ values were added as covariate to the model, to correct for baseline differences.

Regression analyses were performed for mean symptom severity scores (YGTSS for TS, Y-BOCS for OCD) measured during the baseline scan with baseline $\text{BP}_{\text{ND}}$ as independent variable and severity scores as dependent variables. Similarly, changes in symptom severity (difference between Y-BOCS and YGTSS scores measured immediately before and 20 minutes after injection of amphetamine) were correlated to $\Delta \text{BP}_{\text{ND}}$ images.
<table>
<thead>
<tr>
<th></th>
<th>Tourette’s syndrome</th>
<th>OCD</th>
<th>healthy controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mean</td>
<td>range</td>
<td>SD</td>
</tr>
<tr>
<td>Age</td>
<td>31.0</td>
<td>20-45</td>
<td>8.1</td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>8/4</td>
<td>4/8</td>
<td></td>
</tr>
<tr>
<td>Number of current tics (0-37)</td>
<td>10.7</td>
<td>4-23</td>
<td>6.2</td>
</tr>
<tr>
<td>YGTSS (0-50)</td>
<td>17.0</td>
<td>7-28</td>
<td>7.8</td>
</tr>
<tr>
<td>Y-BOCS (0-40)</td>
<td>5.1</td>
<td>0-15</td>
<td>5.5</td>
</tr>
<tr>
<td>HAM-D (0-68)</td>
<td>2.1</td>
<td>0-8</td>
<td>2.6</td>
</tr>
<tr>
<td>HAM-A (0-56)</td>
<td>2.9</td>
<td>0-16</td>
<td>4.7</td>
</tr>
</tbody>
</table>

*Chi-square, YGTSS = Yale Global Tic Severity Scale, Y-BOCS = Yale Brown Obsessive Compulsive Scale, HAM-D = Hamilton Depression Rating Scale, HAM-A = Hamilton Anxiety Rating Scale
Results

Demographic data

Twelve patients with TS (4 women), 12 patients with OCD (8 women) and 12 healthy control subjects (8 women) participated in the study. Subject characteristics are provided in Table 1. Groups were matched for age. For the TS group, the mean number of current tics at baseline ranged from 4 to 23 (overall mean 11±6) with a mean YGTSS score of 19±8, and the mean number of current obsessions or compulsions was 9±8, with a mean Y-BOCS severity score of 5±6. For the OCD group, the mean Y-BOCS score was 24±6. OCD symptoms were of the following subtypes: washing, aggressive thoughts, forbidden thoughts, symmetry/ordering and perfectionism/doubt.

Baseline BP\textsubscript{ND} and amphetamine induced BP\textsubscript{ND} changes

Differences in baseline BP\textsubscript{ND} between healthy controls, TS and OCD are listed in Table 4.2. Omnibus testing revealed significant between-group differences in bilateral putamen extending into bilateral caudate nucleus, with highest baseline BP\textsubscript{ND} values in healthy controls, lowest values in TS patients and intermediate values in OCD patients (see Figure 4.1). Post hoc testing confirmed that baseline BP\textsubscript{ND} was significantly decreased in TS patients versus healthy controls in bilateral putamen. Baseline BP\textsubscript{ND} was decreased in OCD patients versus healthy controls in left ventral putamen at trend level. Baseline BP\textsubscript{ND} differences between OCD and TS patients were not statistically significant.

Table 4.2 Areas with significant differences in baseline BP\textsubscript{ND} between groups

<table>
<thead>
<tr>
<th>Region</th>
<th>MNI-Coordinates</th>
<th>Cluster size</th>
<th>Z-score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>x</td>
<td>y</td>
<td>z</td>
</tr>
<tr>
<td>Controls&gt;OCD&gt;TS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left putamen</td>
<td>-22</td>
<td>2</td>
<td>-2</td>
</tr>
<tr>
<td>Right putamen</td>
<td>34</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Controls&gt;TS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left putamen</td>
<td>-22</td>
<td>0</td>
<td>-2</td>
</tr>
<tr>
<td>Right putamen</td>
<td>34</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Controls&gt;OCD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left putamen</td>
<td>-14</td>
<td>6</td>
<td>-8</td>
</tr>
</tbody>
</table>

* p<0.005 uncorrected, **p<0.05 FWE corrected; BP\textsubscript{ND}= non displaceable binding potential
Main effects of amphetamine administration on $BP_{ND}$ for all groups are shown in Figure 4.2. Displacement was present in bilateral striatum (putamen and caudate nucleus), being most pronounced in healthy controls. A group by displacement effect at trend level in the left ventral caudate (MNI coordinates: -14 26 -2, 8 voxels, $Z=2.75$, $p<0.005$) suggested decreased $BP_{ND}$ displacement in TS, but these differences disappeared after correcting for baseline binding.

An omnibus test showed no significant between-group differences in $BP_{ND}$ after administration of amphetamine.
Behavioral response correlates

Following amphetamine administration, tic severity increased significantly in the TS group (p=0.003), with a mean increase of 3.5±4.6 points on the YGTSS. This increase in tic severity correlated positively (rho=0.85) with displacement in right ventral caudate at a borderline significance level (Figure 4.3, Table 4.3). A negative correlation at trend level (p=0.005, uncorrected) between baseline tic levels and baseline BP was found in left ventral putamen and right ventral caudate (Table 4.3). Finally, a negative correlation

Table 4.3 Correlations between YGTSS scores and BP<sub>ND</sub> for the baseline scan.

<table>
<thead>
<tr>
<th>Region</th>
<th>MNI Coordinates</th>
<th>Cluster size</th>
<th>Z-score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right ventral caudate</td>
<td>18 10 -8</td>
<td>17</td>
<td>3.51**</td>
</tr>
<tr>
<td>Negative correlation BP&lt;sub&gt;ND&lt;/sub&gt; at baseline and YGTSS at baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left ventral putamen</td>
<td>-14 14 -2</td>
<td>3</td>
<td>2.55*</td>
</tr>
<tr>
<td>Negative correlation BP&lt;sub&gt;ND&lt;/sub&gt; post amphetamine and YGTSS post amphetamine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right ventral caudate</td>
<td>6 12 0</td>
<td>19</td>
<td>3.60***</td>
</tr>
</tbody>
</table>

*p<0.005 uncorrected, ** p<0.001 uncorrected (p=0.06 FWE corrected), *** p<0.05 FWE corrected.
YGTSS= Yale Global Tic Severity Scale

Figure 4.3:

Left: Regions showing a significant correlation between changes in tic severity and DA release in the TS group. Right: Scatter plot illustrating correlation between DA release and change in tic severity at MNI coordinate 18 10 -8 (right ventral caudate).
(rho = -0.75), between post amphetamine YGTSS and post amphetamine BPND was found in the right ventral striatum.

In OCD patients, correlations between OCD severity and baseline BPND and between changes in Y-BOCS and displacement were not statistically significant.

Discussion

The current [11C]raclopride PET study aimed to directly compare dopaminergic neurotransmission in TS patients without OCD symptoms, OCD patients without tics and healthy controls. Both TS and OCD patients showed lower striatal D2/3 receptor binding at baseline than healthy controls, although in the OCD group only at trend level. There were no significant differences between amphetamine-induced changes in BPND between the three groups. Tic severity in TS patients increased after the amphetamine challenge, which was correlated with the displacement in right ventral striatum, whereas no changes in symptom severity in OCD patients were observed.

Baseline [11C]raclopride binding

The finding of decreased baseline [11C]raclopride BPND in TS is in contrast with other PET studies, in which no differences in binding between TS and controls were found (Singer et al., 2002; Wong et al., 2008; Turjanski et al., 1994). Differences in PET scan acquisition, data analysis methodology, and patient characteristics may have accounted for these previous discrepant findings. Interestingly, a trend for a negative correlation between baseline BPND and tic severity was found, suggesting that decreased baseline BPND is indeed a pathological feature of TS.

The observation of low baseline striatal [11C]raclopride binding in OCD at trend level is in line with other SPECT and PET studies, substantiating the hypothesis of dopaminergic dysfunction in OCD. Using [123I]iodobenzamide ([123I]IBZM) SPECT, Denys et al. (2004) showed significantly decreased D2/3 receptor availability in left caudate nucleus within a group of 10 OCD patients compared with 10 age matched healthy controls. Schneier et al. (Schneier et al., 2008) found comparable striatal D2/3 decrease in 8 predominantly drug-naïve OCD patients compared with 7 control subjects. Perani et al. (2008) demonstrated significantly decreased striatal [11C]raclopride binding in dorsal caudate, dorsal putamen and ventral striatum of 9 drug-naïve OCD patients compared with 9 controls. D2/3 alterations were more prominent in ventral striatum.

Decreased baseline [11C]raclopride binding to striatal D2/3 receptors, observed in both TS and OCD, may be due to several mechanisms. It may result from (1) decreased D2/3 receptor density and/or affinity, for instance due to receptor internalization, (2) increased levels of endogenous dopamine competing with the radiotracer, or (3) a combination of these phenomena. To assess whether increased levels of endogenous dopamine are the most plausible explanation for the lower baseline BPND observed in both patient groups, a dopamine depletion study should be conducted, as has been done...
in patients with schizophrenia (Abi-Dargham et al., 2009). If confirmed, the tonic/phasic model of DA release (Grace and Bunney, 1983) could explain these abnormalities in dopamine neurotransmission in TS. The single-spike “tonic” firing pattern supplies a constant low extrasynaptic concentration of DA, whereas burst firing of the neurons leads to massive DA release into the synapse which is named the “phasic” response. Amphetamine induced DA release is believed to mimic this phasic response (Grace and Bunney, 1983). Synaptic DA concentrations measured during the baseline scan are thus likely to reflect a combination of both tonic and phasic DA responses during rest. As such, increased endogenous DA levels at baseline in both patient groups may be a result of increased phasic firing at rest, supporting a hyperdopaminergic state that has been hypothesized to underlie TS and OCD (Denys et al., 2004; Wong et al., 2008).

**Changes in BP_{ND} following amphetamine challenge**

Contrary to previous studies, TS patients did not show increased amphetamine induced DA release compared to controls. Differences in patient characteristics and methodology may have accounted for these discrepant findings. Wong and colleagues (Wong et al., 2008) studied a sample in which the majority of the TS patients (10 out of 14) were also diagnosed with OCD. These authors showed that only the subset of TS+OCD patients display significantly increased DA release in the ventral striatum as compared to controls. This raises the question if increased DA release might be related to either TS or OCD, or both. Our sample consisted of OCD patients without tics and TS patients without OCD to differentiate between the contributions of either disorder to striatal dopamine dysregulation. Since our results show no increased DA release in OCD, it is unlikely that OCD was responsible for increased DA release in the previous study. However, we did not find increased DA release in the TS group either, which may have been due to the fact that our sample was less severely affected, as a result of excluding patients with comorbidity. Moreover, TS with comorbid OCD is associated with changes in limbic brain areas both structurally as well as functionally, whereas TS without OCD is associated with abnormalities in motor areas (Worbe et al., 2010a; Worbe et al., 2011). Thus, the finding of increased ventral striatal DA release in the study by Wong et al. (2008) may be specific for TS patients with associated OCD, which were excluded from our study.

A second difference between the current study and previous studies is related to PET scan acquisition protocols. In these previous studies, amphetamine was administered 5 minutes before bolus injection of \(^{[1]}\text{C}\)raclopride and the start of the emission scan. In the present study a bolus plus continuous infusion protocol was used and emission scanning was performed under steady state conditions. It has been argued that scanning under steady state conditions is less susceptible to artifacts due to changes in cerebral blood flow and washout rate of the tracer (Carson et al., 1997; Laruelle, 2000), which is preferable when administering amphetamine as this may affect blood flow. Another
The advantage of the bolus plus constant infusion protocol is that after administration of amphetamine, subjects stayed outside the scanner during infusion, which enabled us to record changes in symptom severity. Amphetamine-induced DA release in the ventral striatum was related to increased tic severity, which provides evidence that ventral striatal DA release is related to the pathophysiology of tics. This finding is substantiated by the correlation between tic severity and dopaminergic tone (at baseline as well as post amphetamine), but seems to be difficult to reconcile with the low to normal amphetamine induced DA release in the TS group as compared to controls. However, it may be argued that only a small increase in DA may suffice to cause progressive symptoms, when DA concentrations are already increased at rest in the TS group.

Tics tend to follow a waxing and waning course, are partially under voluntary control and tic severity often decreases after adolescence (1), which led to the hypothesis that tics decrease with increasing prefrontal control over (abnormal) striatal function (Peterson et al., 2001). Indeed, cognitive techniques have been successful in controlling tics. Grace et al. (Grace et al., 2007) noted that both increased tonic and phasic DA release can shift the balance from medial prefrontal cortical (mPFC) control towards limbic control of goal directed behavior. Increased tonic DA, acting on D₂ receptors, attenuates mPFC activity, whereas increased phasic DA, acting on D₁ receptors enhances limbic control. In this model, D₂ receptor antagonists, the main pharmacological treatment for TS, increase mPFC control and may thus restore dopaminergic balance. On the other hand, increased ventral DA release might result in reinforcement of cortico-striatal circuits, facilitating the progressive formation of tics (Groenewegen et al., 2003; Maia and Frank, 2011; Saka and Graybiel, 2003).

Limitations

Several limitations of our study warrant further discussion. The control and TS group were not well matched for gender, with relatively more females in the control group. Gender differences in both baseline D₂ receptor binding as well as DA release have been observed, and males reportedly to have relatively higher dopamine release than females (Munro et al., 2006) and increased baseline D₂ binding (Pohjalainen et al., 1998). However, as the TS group contained more males than the control group, bias due to gender would have resulted in increased DA release in the TS group and increased baseline binding. Moreover, secondary analyses including gender as a covariate yielded similar results (data not shown). Menstrual phase of the female subjects in our study was not evaluated and might also have influenced D₂ receptor measurements, as was shown in female monkeys (Czoty et al., 2009), but not in humans (Nordstrom et al., 1998). Although our sample was not entirely treatment naïve, only one patient had used a D₂ receptor antagonist in the past, therefore confounding effects of previous neuroleptic use are unlikely.
In our study we compared OCD and TS patients, but excluded TS patients with OCD to investigate the contribution of either disorder; an additional comparison between a group of TS patients with and without OCD, controlling for symptom severity, may further increase our understanding of the similarities and differences between the two disorders.

Unfortunately, individual differences in impulsivity were not assessed. Impulsivity may be one of the explanations for lack of control over tics and compulsive behaviours in TS and OCD. In addition, impulsivity has been associated with baseline binding of \[^{11}\text{C}]\text{raclopride}\) and its displacement after amphetamine (e.g. (Oswald et al., 2007)). Nevertheless, both YGTSS and Y-BOCS contain items for control over tics and compulsions, respectively, and no correlation between scores on these items and \[^{11}\text{C}]\text{raclopride}\) binding or amphetamine induced displacement was observed (data not shown). Finally, although comparable with earlier studies, the sample with twelve subjects in each subject group was modest, so any hypotheses regarding etiology should be made with caution.

Conclusion

Baseline striatal D\(_{2/3}\) receptor binding in TS and OCD was decreased in TS and OCD patients, supporting the hypothesis of chronically increased dopaminergic activity in both disorders. Dopaminergic dysfunction may be a common pathophysiologic mechanism in TS and OCD, explaining considerable overlap between the two disorders in terms of clinical phenomenology.